A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Trial Profile

A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Encenicline (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacokinetics
  • Sponsors FORUM Pharmaceuticals
  • Most Recent Events

    • 14 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 22 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top